US · Healthcare · Medical Devices
EPS came in at 0.10 against a street estimate of -0.27 — a beat of 137.0%.
Analysts rate LENSAR Inc a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $11.33.
| Fund | Stake |
|---|---|
| Brandes Investment Partners & Co | 8.75% |
| Vanguard Capital Management, LLC | 3.28% |
| RBF LLC | 1.54% |
| BlackRock Inc | 1.51% |
| Css LLC | 1.33% |
| Dimensional Fund Advisors, Inc. | 1.23% |
| Kerrisdale Advisers, LLC | 1.13% |
| Millennium Management LLC | 0.98% |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for LENSAR Inc — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-10-18.